Zhengye Biotechnology Clears Nasdaq Minimum Bid Requirement, ZYBT Surges 133.59% on August 6

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) regained compliance with Nasdaq's minimum bid price rule on August 5, 2026 — and the stock responded with a violent move the following session.

As of 12:28 PM EDT on August 6, 2026, ZYBT traded at $2.99, up $1.71 or +133.59% on the day, swinging across a range of $1.26 to $4.29 on volume of 42,995,005 shares, per the company's August 6, 2026 GlobeNewswire dispatch.

The compliance story is straightforward. On May 29, 2026, Nasdaq notified Zhengye that its Class A ordinary shares had closed below $1.00 per share for 30 consecutive business days, triggering a deficiency notice under Nasdaq Listing Rule 5550(a)(2). The company then had to demonstrate a sustained recovery. Nasdaq confirmed in a Compliance Letter dated August 5, 2026, that ZYBT's closing bid price met the $1.00 minimum for the 10 consecutive business days running from July 20, 2026 through August 4, 2026. The deficiency is resolved; the company remains listed on The Nasdaq Capital Market under ticker ZYBT.

For context on the timeline: Zhengye priced its IPO on January 6, 2025, at $4.00 per ordinary share for 1,500,000 shares, per the GlobeNewswire dispatch. The deficiency notice arrived May 29, 2026. The company needed the full 10-day cure window to satisfy Nasdaq's requirement.

Zhengye operates through Jilin Zhengye Biological Products Co., Ltd., based in Jilin, China. The company has been in the veterinary vaccine business for over 20 years, per the GlobeNewswire release, focusing on research, development, manufacturing, and sales of vaccines for livestock and other animals. Its product lines cover swine, cattle, goats, sheep, poultry, and dogs, and span monovalent, polyvalent, combined, and combined-and-polyvalent vaccine formats.

No executive statement accompanied the compliance announcement.

The broader market on August 6, 2026 was mixed. The Nasdaq composite fell 0.47% and the Russell 2000 slipped 0.59%, per TheStreet — a backdrop that makes ZYBT's intraday move stand out on its own compliance catalyst rather than any sector tailwind.

Per the August 6, 2026 GlobeNewswire release, the company has cleared the immediate compliance hurdle; no grace period, condition, or follow-on obligation is disclosed in that filing.